Sanofi $SNY Stock Purchased by Ethic Inc.

Ethic Inc. raised its holdings in shares of Sanofi (NASDAQ:SNY) by 12.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,079 shares of the company’s stock after acquiring an additional 16,290 shares during the quarter. Ethic Inc.’s holdings in Sanofi were worth $5,982,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Root Financial Partners LLC purchased a new stake in shares of Sanofi in the third quarter valued at about $27,000. Western Wealth Management LLC acquired a new position in shares of Sanofi during the 1st quarter worth approximately $29,000. Signature Equity Partners LLC raised its position in shares of Sanofi by 322.2% during the 3rd quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock worth $35,000 after purchasing an additional 654 shares during the last quarter. Financial Network Wealth Advisors LLC lifted its stake in Sanofi by 103.3% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $38,000 after buying an additional 463 shares in the last quarter. Finally, Provenance Wealth Advisors LLC lifted its stake in Sanofi by 359.8% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 2,322 shares of the company’s stock valued at $96,000 after buying an additional 1,817 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Performance

Shares of SNY opened at $48.12 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.64 and a current ratio of 1.12. The company has a market capitalization of $116.66 billion, a price-to-earnings ratio of 23.82, a PEG ratio of 1.30 and a beta of 0.31. The company’s 50 day simple moving average is $42.36 and its 200 day simple moving average is $44.35. Sanofi has a 1 year low of $39.07 and a 1 year high of $52.68.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48. The firm had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. Sanofi’s revenue was up 16.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.91 earnings per share. On average, sell-side analysts predict that Sanofi will post 5.06 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday. DZ Bank reissued a “buy” rating on shares of Sanofi in a report on Friday, July 31st. HSBC restated a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Wolfe Research started coverage on Sanofi in a research note on Friday, October 9th. They set a “peer perform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $53.00.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world.

Sanofi traces its origins to a company established in France in 1973.